Picard Medical Inc 的盈利质量评分为 B+/56.23956。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Picard Medical Inc 何时发布财报?
Picard Medical Inc 的下一份财报预计在 发布
Picard Medical Inc 的预期收益是多少?
根据华尔街分析师的预测,Picard Medical Inc 的预期收益为 $
Picard Medical Inc 是否超出收益预期?
Picard Medical Inc 最近的收益为 $, 预期。
关键数据
前收盘价
$1.05
开盘价
$1.04
当日区间
$0.99 - $1.07
52周范围
$0.96 - $13.68
交易量
152.2K
平均成交量
809.9K
股息收益率
--
每股收益(TTM)
--
市值
$75.1M
什么是 PMI?
Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. The company is headquartered in Tucson, Arizona and currently employs 75 full-time employees. The company went IPO on 2025-08-29. SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.